David Martin, M-CAM Founder, discusses the EpiPen pricing saga and his view that the patent office gave Mylan an unjustified monopoly on the drug.
The FDA and Congress enabled Mylan to secure a monopoly on EpiPens and then jack up the prices, says this intellectual-property expert. So why can't they just end it?
Investor Craig Cooper provides his insights on what happened during his encounter with a motorized paddle board, action-packed helmet cam and a high endurance tent. Adventure Capitalists premiere episodes Mondays 10P ET/9P PT.